MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
3d rendered medically accurate illustration of white blood cells attacking a cancer cell

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International Convention BUFFALO, N.Y., May 29, 2019 /PRNewswire/ -- MimiVax LLC, a clinical-stage…

Continue Reading
SurVaxM Phase I Completed
A syringe with the needle point to the vaccine vial on the colorful abstract background

SurVaxM Phase I Completed

Phase I clinical trial results of SurVaxM presented at AACR Annual Meeting 2015 in Philadelphia BUFFALO, N.Y. — A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in…

Continue Reading